Guyana’s shore base capacity: Eight projects approved over four years 

Must Read

Growing offshore activity has seen Guyana’s shore base capacity expand considerably since 2020. The Ministry of Public Works told OilNOW approval was given for eight projects over this period. 

Among the greenlit projects was the expansion works at the Guyana Shore Base Inc. (GYBSI) Houston facility. The set expansion is expected to occur on 170 acres of canefield lands located at the Industrial Estate.

There is also the massive Vreed-en-Hoop Shore Base Inc. (VEHSI). VEHSI is a joint venture between NRG Holdings Inc., a Guyanese consortium of majority locally-owned businesses — National Hardware Guyana Limited, ZRN Investments Incorporated, and Jan De Nul Group. It is part of the larger Port of Vreed-en-Hoop, which will be Guyana’s first modern multi-purpose port situated in Foreshore Plantation, West Bank Demerara. VEHSI will serve as ExxonMobil’s special purpose vehicle for the Yellowtail development – Guyana’s fourth oil development.

Additionally, there is the Tristar Versailles Shore Base; Hadi’s World Shore Base Facility at Peter’s Hall, East Bank Demerara; the Diamond Shore Base Inc. at Friendship, East Bank Demerara; Orinduik Development Inc. Shore Base at Lusignan, East Coast Demerara; and the Friendship Shore Base Inc. at Friendship East Bank Demerara. 

There is also the Baker Hughes Super Center facility, at Land of Canaan on the East Bank of Demerara. It was built together with Baker Hughes’ existing completion warehouse and liquid mud and completion fluids plant, providing full support to customers in Guyana and Suriname.

At present, Guyana has three oil developments online in the ExxonMobil-operated Stabroek Block. A fourth will be added next year. Exxon has discovered 11 billion barrels of oil offshore Guyana. Over 30 commercial discoveries have been made. 

- ADVERTISEMENT -
spot_img

Partnered Events

Latest News

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology

Q1 2024 Trading Update (Unaudited)COPENHAGEN--(BUSINESS WIRE)--In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates...

More Articles Like This